3-hydroxylidocaine has been researched along with erythromycin in 2 studies
| Studies (3-hydroxylidocaine) | Trials (3-hydroxylidocaine) | Recent Studies (post-2010) (3-hydroxylidocaine) | Studies (erythromycin) | Trials (erythromycin) | Recent Studies (post-2010) (erythromycin) |
|---|---|---|---|---|---|
| 10 | 2 | 1 | 14,524 | 1,138 | 1,926 |
| Protein | Taxonomy | 3-hydroxylidocaine (IC50) | erythromycin (IC50) |
|---|---|---|---|
| 30S ribosomal protein S6 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S7 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L15 | Escherichia coli K-12 | 1.156 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.045 | |
| 50S ribosomal protein L10 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L11 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L19 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L1 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L20 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L27 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L28 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L29 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L31 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L32 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L33 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L34 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L35 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L36 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S10 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S11 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S12 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S13 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S16 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S18 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S19 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S20 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S2 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S3 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S4 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S5 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S8 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S9 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L13 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L14 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L16 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L23 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S15 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L17 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L21 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L30 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L6 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S14 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S17 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S1 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L18 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L2 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L3 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L24 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L4 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L22 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L5 | Escherichia coli K-12 | 1.156 | |
| 30S ribosomal protein S21 | Escherichia coli K-12 | 1.156 | |
| 50S ribosomal protein L25 | Escherichia coli K-12 | 1.156 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.039 | |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | 1.156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backman, JT; Kivistö, KT; Neuvonen, PJ; Taavitsainen, P; Wang, JS; Wen, X | 1 |
| Isohanni, MH; Neuvonen, PJ; Olkkola, KT | 1 |
1 trial(s) available for 3-hydroxylidocaine and erythromycin
| Article | Year |
|---|---|
Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Topics: Administration, Oral; Adult; Anesthetics, Local; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Erythromycin; Female; Fluvoxamine; Half-Life; Humans; Lidocaine; Male; Metabolic Clearance Rate; Nausea | 2006 |
1 other study(ies) available for 3-hydroxylidocaine and erythromycin
| Article | Year |
|---|---|
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Topics: Anesthetics, Local; Autopsy; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Fluvoxamine; Humans; In Vitro Techniques; Ketoconazole; Lidocaine; Male; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases | 1999 |